MELBOURNE, Australia, June 29, 2026 /PRNewswire/ — Avecho Biotechnology Limited (ASX: AVE) ("Avecho" or "the Company") has announced it will continue with recruitment for its world-first Phase III insomnia program following a positive interim analysis evaluating its TPM®-enhanced…
News provided by PR Newswire.
